JP2016006125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016006125A5 JP2016006125A5 JP2015196105A JP2015196105A JP2016006125A5 JP 2016006125 A5 JP2016006125 A5 JP 2016006125A5 JP 2015196105 A JP2015196105 A JP 2015196105A JP 2015196105 A JP2015196105 A JP 2015196105A JP 2016006125 A5 JP2016006125 A5 JP 2016006125A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- ala
- analog
- intestinal
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TWSALRJGPBVBQU-PKQQPRCHSA-N Glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 208000004232 Enteritis Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000000968 intestinal Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 230000002496 gastric Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010009839 Coeliac disease Diseases 0.000 claims 2
- 101700062901 DPP Proteins 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 206010025476 Malabsorption Diseases 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 2
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 2
- 201000008286 diarrhea Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001071 malnutrition Effects 0.000 claims 2
- 235000000824 malnutrition Nutrition 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 231100000486 side effect Toxicity 0.000 claims 2
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical group CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 206010061428 Decreased appetite Diseases 0.000 claims 1
- 102100003818 GCG Human genes 0.000 claims 1
- 101710042131 GCG Proteins 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 claims 1
- 206010059017 Intestinal mass Diseases 0.000 claims 1
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010044697 Tropical sprue Diseases 0.000 claims 1
- 206010068760 Ulcers Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001079 digestive Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 108010074605 gamma-Globulins Proteins 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 230000002588 toxic Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
Claims (15)
- インビボでの腸質量の増加をひき起こす生物活性を有する、以下の式:
R 1 −His−Gly−Glu−Gly−X5−Phe−Ser−Ser−Glu−Leu−X11−Thr−Ile−Leu−Asp−Ala−Leu−Ala−Ala−Arg−Asp−Phe−Ile−Ala−Trp−Leu−Ile−Ala−Thr−Lys−Ile−Thr−Asp−Z 2 −R 2
{式中、
− R 1 は水素、C 1-4 アルキル、アセチル、ホルミル、ベンゾイル又はトリフルオロアセチルであり、
− X5はSer又はThrであり、
− X11はAla、Lys又はSerであり、
− R 2 はNH 2 又はOHであり、
− Z 2 は、ペプチド配列Lys 6 であるか又は不在である。}で表されるグルカゴン様ペプチド2(GLP−2)アナログ、又は薬学的に許容されるその塩。但し、以下の:
1844 H−HGEGTFSSELSTILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;
1846 H−HGEGSFSSELSTILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;
1848 H−HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;
1849 H−HGEGSFSSELATILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;
1852 H−HGEGTFSSELKTILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;
1853 H−HGEGTFSSELSTILDALAARDFIAWLIATKITD−NH 2 ;
1855 H−HGEGSFSSELSTILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;
1857 H−HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK−NH 2 ;及び
1858 H−HGEGSFSSELATILDALAARDFIAWLIATKITD−NH 2 ;
を除く。 - 1818 H−HGDGSFSSELATILDNLAARDFIAWLIQTKKKKKK−NH 2 ;
1819 H−HGDGSFSDELSTILDNLAARDFIAWLIQTKKKKKK−NH 2 ;
1821 H−HGDGSFSDELKTILDNLAARDFIAWLIQTKKKKKKK−NH 2 ;
1822 H−HGDGSFTDELKTILDNLAARDFIAWLIQTKKKKKKK−NH 2 ;
1823 H−HGDGSFTSELKTILDNLAARDFIAWLIQTKKKKKKK−NH 2 ;
1825 H−HGDGSFSSELATILDNLAARDFIAWLIQTK−NH 2 ;
1826 H−HGDGSFSDELNTILDNLAARDFIAWLIQTKITDKKKKKK−NH 2 ;
1827 H−HGDGSFTDELSTILDNLAARDFIAWLIQTKKKKKKK−NH 2 ;
1828 H−HGDGSFTSELSTILDNLAARDFIAWLIQTKKKKKKK−NH 2 ;
1829 H−HGDGSFSSELSTILDNLAARDFIAWLIQTKKKKKKK−NH 2 ;
1830 H−HGDGSFSDELSTILDNLAARDFIAWLIQTK−NH 2 ;
1831 H−HGDGSFTDELSTILDNLAARDFIAWLIQTK−NH 2 ;
1832 H−HGDGSFTSELSTILDNLAARDFIAWLIQTK−NH 2 ;
1833 H−HGDGSFSSELSTILDNLAARDFIAWLIQTK−NH 2 ;
1834 H−HGDGSFTSELATILDNLAARDFIAWLIQTK−NH 2 ;
1835 H−HGDGSFSDELKTILDNLAARDFIAWLIQTK−NH 2 ;
1836 H−HGDGSFTDELKTILDNLAARDFIAWLIQTK−NH 2 ;
1839 H−HGDGSFSDELATILDNLAARDFIAWLIQTKITDKKKKKK−NH 2 ;
1840 H−HGDGSFSDELATILDNLAARDFIAWLIQTKITD−NH 2 ;
1841 H−HGDGSFSDELATILDNLAARDFIAWLIQTK−NH 2 ;
1842 H−HGDGSFTSELKTILDNLAARDFIAWLIQTK−NH 2 ;
1843 H−HGDGSFTDELATILDNLAARDFIAWLIQTK−NH 2 ;及び
1854 H−HGEGTFSDELSTILDALAARDFIAWLIATKITD−NH 2 からなる群から選ばれるGLP−2アナログ又は薬学的に許容されるその塩。 - 担体と混和した状態の、請求項1又は2に記載のGLP−2アナログ又はその塩を含む医薬組成物。
- 前記GLP−2アナログの塩が薬学的に許容される酸付加塩である、請求項2に記載の医薬組成物。
- 注射又は輸液による投与に適した液体として処方されるか又は前記GLP−2アナログの徐放をひき起こすように処方されている、請求項3又は4に記載の医薬組成物。
- 胃及び腸関連の障害の治療及び/又は予防のための医薬の製造のための、請求項1又は2に記載のGLP−2アナログの使用。
- 前記胃及び腸関連の障害が、潰瘍、胃炎、消化障害、吸収不良症候群、短腸症候群、盲管症候群、炎症性腸疾患、セリアック病、熱帯性スプルー、低ガンマグロブリン血スプルー、腸炎、限局性腸炎(クローン病)、潰瘍性大腸炎、下痢関連過敏性腸症候群、小腸損傷又は短腸症候群である、請求項6に記載の使用。
- 前記胃及び腸関連障害が、放射線腸炎、感染性又は感染後腸炎、又は毒性その他の化学療法薬に起因する小腸損傷である、請求項6に記載の使用。
- 化学療法又は放射線治療の副作用の治療及び/又は予防のための医薬の製造のための、請求項1又は2に記載のGLP−2アナログの使用。
- 前記副作用が、化学療法による下痢、腹部疝痛又は嘔吐、あるいは化学療法又は放射線治療の結果としての腸上皮の構造的及び機能的損傷である、請求項9に記載の使用。
- 新生児、骨粗しょう症又はDPP−IV(ジペプチジルペプチダーゼ−IV)媒介型症状における腸機能欠陥の治療用の医薬の製造のための、請求項1又は2に記載のGLP−2アナログの使用。
- 栄養失調関連症状の治療及び/又は予防のための医薬の製造のための、請求項1又は2に記載のGLP−2アナログの使用。
- 前記栄養失調症関連症状が、悪液質又は拒食症である、請求項12に記載の使用。
- 薬学的に許容される担体とともに、癌化学療法薬、及び請求項1又は2に記載のGLP−2アナログを含む、治療用キット。
- 薬学的に許容される担体とともに、癌化学療法薬、及び請求項1又は2に記載のGLP−2アナログを含む医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67806605P | 2005-05-04 | 2005-05-04 | |
US60/678,066 | 2005-05-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013077830A Division JP5876434B2 (ja) | 2005-05-04 | 2013-04-03 | グルカゴン様ペプチド−2(glp−2)アナログ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016006125A JP2016006125A (ja) | 2016-01-14 |
JP2016006125A5 true JP2016006125A5 (ja) | 2016-03-10 |
JP6272284B2 JP6272284B2 (ja) | 2018-01-31 |
Family
ID=36649773
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008509505A Active JP5405105B2 (ja) | 2005-05-04 | 2006-05-04 | グルカゴン様ペプチド−2(glp−2)アナログ |
JP2013077830A Expired - Fee Related JP5876434B2 (ja) | 2005-05-04 | 2013-04-03 | グルカゴン様ペプチド−2(glp−2)アナログ |
JP2015196105A Active JP6272284B2 (ja) | 2005-05-04 | 2015-10-01 | グルカゴン様ペプチド−2(glp−2)アナログ |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008509505A Active JP5405105B2 (ja) | 2005-05-04 | 2006-05-04 | グルカゴン様ペプチド−2(glp−2)アナログ |
JP2013077830A Expired - Fee Related JP5876434B2 (ja) | 2005-05-04 | 2013-04-03 | グルカゴン様ペプチド−2(glp−2)アナログ |
Country Status (25)
Country | Link |
---|---|
US (7) | US7563770B2 (ja) |
EP (4) | EP3473646A1 (ja) |
JP (3) | JP5405105B2 (ja) |
KR (3) | KR101200227B1 (ja) |
CN (2) | CN101171262B (ja) |
AT (1) | ATE498631T1 (ja) |
AU (1) | AU2006242998B2 (ja) |
BR (1) | BRPI0610091B1 (ja) |
CA (1) | CA2607150C (ja) |
CY (1) | CY1111411T1 (ja) |
DE (1) | DE602006020123D1 (ja) |
DK (1) | DK1877435T4 (ja) |
EA (1) | EA014184B1 (ja) |
ES (1) | ES2361095T5 (ja) |
HK (1) | HK1108898A1 (ja) |
IL (3) | IL186746A (ja) |
MX (1) | MX2007013431A (ja) |
NO (1) | NO345236B1 (ja) |
NZ (4) | NZ562943A (ja) |
PL (1) | PL1877435T5 (ja) |
PT (1) | PT1877435E (ja) |
SI (1) | SI1877435T2 (ja) |
UA (1) | UA95235C2 (ja) |
WO (1) | WO2006117565A2 (ja) |
ZA (2) | ZA200709384B (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
SI2386310T1 (sl) | 2002-08-28 | 2019-03-29 | Dyax Corp. | Metode za ohranjanje organov in tkiv |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
BRPI0610091B1 (pt) | 2005-05-04 | 2021-08-03 | Zealand Pharma A/S | Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico |
WO2007106746A2 (en) * | 2006-03-10 | 2007-09-20 | Dyax Corp. | Formulations for ecallantide |
US8232245B2 (en) † | 2006-07-26 | 2012-07-31 | Sandoz Ag | Caspofungin formulations |
MX2009002756A (es) * | 2006-09-12 | 2009-05-25 | Cosmo Technologies Ltd | Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas. |
CN101573376B (zh) * | 2006-11-08 | 2013-11-06 | 西兰制药公司 | 选择性胰高血糖素样肽-2(glp-2)类似物 |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
KR20090035279A (ko) * | 2007-10-05 | 2009-04-09 | 경희대학교 산학협력단 | 위장관 손상 예방 및 치료용 조성물 |
US20090110713A1 (en) * | 2007-10-31 | 2009-04-30 | Florencia Lim | Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices |
WO2010080833A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
CN102942626B (zh) * | 2009-03-05 | 2015-11-04 | 江苏豪森医药集团有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
HUE057244T2 (hu) | 2010-01-06 | 2022-04-28 | Takeda Pharmaceuticals Co | Plazma kallikreint kötõ fehérjék |
CA2846680C (en) | 2010-08-30 | 2019-06-25 | Takeda Gmbh | Solid phase synthesis of h[gly2]glp-2 |
JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
CN102212127B (zh) * | 2011-05-17 | 2015-02-04 | 上海景泽生物技术有限公司 | 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途 |
CN102924589B (zh) * | 2011-08-11 | 2016-08-24 | 中肽生化有限公司 | 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途 |
US20160137711A1 (en) | 2011-09-12 | 2016-05-19 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
EP3406347A3 (en) | 2012-02-27 | 2019-02-13 | Amunix Operating Inc. | Xten conjugate compositions and methods of making same |
TR201802689T4 (tr) | 2012-05-03 | 2018-03-21 | Zealand Pharma As | Glukagon benzeri peptit-2 (glp-2) analogları. |
US20150038674A1 (en) * | 2013-08-05 | 2015-02-05 | Bayrak Bertan Boran | Use of glp-2 analogues in pulmonary diseases for therapeutic purpose |
JP6719384B2 (ja) | 2014-03-27 | 2020-07-15 | ダイアックス コーポレーション | 糖尿病黄斑浮腫の治療のための組成物および方法 |
US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
US20170087216A1 (en) * | 2015-09-17 | 2017-03-30 | Helsinn Healthcare Sa | Therapeutic Uses of Elsiglutide |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
CN107987170B (zh) | 2016-10-27 | 2018-12-18 | 浙江道尔生物科技有限公司 | 一种用于治疗肠道疾病的融合蛋白 |
WO2018104559A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
KR102587196B1 (ko) * | 2016-12-09 | 2023-10-10 | 질랜드 파마 에이/에스 | Glp-1/glp-2 이중 효능제 |
JP6563614B1 (ja) * | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア/エス | アシル化glp−1/glp−2二重アゴニスト |
WO2018142363A1 (en) * | 2017-02-06 | 2018-08-09 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use compositions of glp-2 analogues through self-administrable devices |
DK3638291T3 (da) * | 2017-06-16 | 2021-10-18 | Zealand Pharma As | Dosisregimer til indgivelse af glucagon-lignende-peptid-2 (GLP-2)-analoger |
MX2020004453A (es) * | 2017-09-28 | 2020-07-24 | Hanmi Pharm Ind Co Ltd | Conjugados de accion prolongada de derivados de glp-2. |
WO2019086559A1 (fr) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
EP3628682A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
EP3628683A1 (en) * | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
KR20210126088A (ko) * | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
CN110305223B (zh) | 2019-06-26 | 2022-05-13 | 重庆派金生物科技有限公司 | 重组串联融合蛋白制备目标多肽的方法 |
WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
CN115697375A (zh) * | 2020-04-03 | 2023-02-03 | 韩美药品株式会社 | 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物 |
UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
CN111560062A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Elisiglutide的制备方法 |
JP2023529478A (ja) | 2020-06-09 | 2023-07-10 | ベクティブバイオ エージー | アプラグルチドの製造、配合、及び投薬 |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
AU2021402687A1 (en) | 2020-12-16 | 2023-06-22 | Zealand Pharma A/S | Use of glp-2 analogues in patients with renal insufficiency |
CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
TW202327643A (zh) | 2021-09-10 | 2023-07-16 | 丹麥商西蘭製藥公司 | 包含類升糖素肽2(glp-2)類似物之組合物之調配方法 |
WO2023118416A1 (en) | 2021-12-23 | 2023-06-29 | Zealand Pharma A/S | Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues |
WO2024068933A1 (en) | 2022-09-30 | 2024-04-04 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs) |
CN116751278B (zh) * | 2023-06-21 | 2024-02-13 | 杭州信海医药科技有限公司 | 一种Glepaglutide的制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
JP2961045B2 (ja) * | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
AU710818B2 (en) † | 1996-03-01 | 1999-09-30 | Novo Nordisk A/S | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
AU733857B2 (en) † | 1996-04-12 | 2001-05-31 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
US5994500A (en) * | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
US20020025933A1 (en) | 1996-08-30 | 2002-02-28 | Knudsen Liselotte Bjerre | GLP-2 derivatives |
CA2265900C (en) | 1996-09-09 | 2007-07-31 | Zealand Pharmaceuticals A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
DK0981362T3 (da) † | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
EP1052994A2 (en) * | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
WO2002022151A2 (en) | 2000-09-18 | 2002-03-21 | Osteometer Bio Tech A/S | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
WO2002066062A2 (en) * | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
AU2002233089B2 (en) * | 2001-02-16 | 2005-12-22 | Conjuchem Biotechnologies Inc. | Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders |
WO2002098348A2 (en) | 2001-06-01 | 2002-12-12 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
WO2004035624A2 (en) † | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
JP2007525425A (ja) * | 2003-03-24 | 2007-09-06 | ノボ ノルディスク アクティーゼルスカブ | Glp−2誘導体 |
TW200526254A (en) * | 2003-09-19 | 2005-08-16 | Novo Nordisk As | Novel GLP-1 derivatives |
EP1809318B1 (en) * | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
BRPI0610091B1 (pt) | 2005-05-04 | 2021-08-03 | Zealand Pharma A/S | Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico |
CN101573376B (zh) * | 2006-11-08 | 2013-11-06 | 西兰制药公司 | 选择性胰高血糖素样肽-2(glp-2)类似物 |
WO2010070251A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
CN111701028A (zh) | 2011-05-18 | 2020-09-25 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抵抗的改进的肽医药 |
-
2006
- 2006-05-04 BR BRPI0610091-0A patent/BRPI0610091B1/pt active IP Right Grant
- 2006-05-04 US US11/429,168 patent/US7563770B2/en active Active
- 2006-05-04 MX MX2007013431A patent/MX2007013431A/es active IP Right Grant
- 2006-05-04 ES ES06727006T patent/ES2361095T5/es active Active
- 2006-05-04 PT PT06727006T patent/PT1877435E/pt unknown
- 2006-05-04 SI SI200630985T patent/SI1877435T2/sl unknown
- 2006-05-04 NZ NZ562943A patent/NZ562943A/en not_active IP Right Cessation
- 2006-05-04 NZ NZ591179A patent/NZ591179A/en not_active IP Right Cessation
- 2006-05-04 CA CA2607150A patent/CA2607150C/en active Active
- 2006-05-04 KR KR1020077028167A patent/KR101200227B1/ko active IP Right Grant
- 2006-05-04 KR KR1020117015195A patent/KR101242951B1/ko active IP Right Grant
- 2006-05-04 AT AT06727006T patent/ATE498631T1/de active
- 2006-05-04 CN CN2006800152135A patent/CN101171262B/zh active Active
- 2006-05-04 EP EP18206332.1A patent/EP3473646A1/en active Pending
- 2006-05-04 EP EP06727006.6A patent/EP1877435B2/en active Active
- 2006-05-04 EA EA200702408A patent/EA014184B1/ru unknown
- 2006-05-04 EP EP10009231A patent/EP2295451A1/en not_active Withdrawn
- 2006-05-04 JP JP2008509505A patent/JP5405105B2/ja active Active
- 2006-05-04 WO PCT/GB2006/001633 patent/WO2006117565A2/en active Application Filing
- 2006-05-04 CN CN201210124331.7A patent/CN102659938B/zh not_active Expired - Fee Related
- 2006-05-04 NZ NZ591178A patent/NZ591178A/en not_active IP Right Cessation
- 2006-05-04 NZ NZ593050A patent/NZ593050A/xx unknown
- 2006-05-04 PL PL06727006T patent/PL1877435T5/pl unknown
- 2006-05-04 DE DE602006020123T patent/DE602006020123D1/de active Active
- 2006-05-04 UA UAA200713558A patent/UA95235C2/ru unknown
- 2006-05-04 EP EP10009232A patent/EP2295452A1/en not_active Withdrawn
- 2006-05-04 AU AU2006242998A patent/AU2006242998B2/en active Active
- 2006-05-04 KR KR1020117015196A patent/KR101242795B1/ko active IP Right Grant
- 2006-05-04 DK DK06727006.6T patent/DK1877435T4/da active
- 2006-11-09 US US11/595,496 patent/US7745403B2/en active Active
-
2007
- 2007-10-18 IL IL186746A patent/IL186746A/en active IP Right Grant
- 2007-10-31 ZA ZA2007/09384A patent/ZA200709384B/en unknown
- 2007-11-23 NO NO20076043A patent/NO345236B1/no unknown
-
2008
- 2008-03-14 HK HK08102990.8A patent/HK1108898A1/xx active IP Right Maintenance
-
2009
- 2009-12-21 US US12/643,233 patent/US8263552B2/en active Active
- 2009-12-21 US US12/643,261 patent/US8163696B2/en active Active
-
2011
- 2011-01-16 IL IL210668A patent/IL210668A/en active IP Right Grant
- 2011-01-16 IL IL210669A patent/IL210669A/en active IP Right Grant
- 2011-01-28 ZA ZA2011/00753A patent/ZA201100753B/en unknown
- 2011-05-05 CY CY20111100436T patent/CY1111411T1/el unknown
-
2012
- 2012-06-28 US US13/536,377 patent/US9125882B2/en active Active
-
2013
- 2013-04-03 JP JP2013077830A patent/JP5876434B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-08 US US14/847,938 patent/US9580487B2/en active Active
- 2015-10-01 JP JP2015196105A patent/JP6272284B2/ja active Active
-
2017
- 2017-01-20 US US15/411,649 patent/US20170137487A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016006125A5 (ja) | ||
JP2008539713A5 (ja) | ||
ES2792848T3 (es) | Politerapia para el tratamiento de infecciones por VHB | |
US10301255B2 (en) | Hepatitis B antiviral agents | |
US10577337B2 (en) | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | |
ES2772754T3 (es) | Pemafibrato para uso en el tratamiento de la enfermedad del hígado graso no alcohólico | |
ES2647216T3 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
JP4632204B2 (ja) | 下痢型過敏性腸症候群治療剤 | |
AU2018227849A1 (en) | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
JP2014077003A5 (ja) | ||
JP2015518818A5 (ja) | ||
WO2015183794A1 (en) | Tgr5 agonist complexes for treating diabetes and cancer | |
RU2010114002A (ru) | Применение фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
UA92327C2 (ru) | Применение n-арилдиазаспироциклических соединений для лечения зависимостей | |
JP2011225596A5 (ja) | ||
RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
JP2015535243A5 (ja) | ||
RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
JPWO2019107530A5 (ja) | ||
MX2022010044A (es) | Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo. | |
US20190070212A1 (en) | Compounds and compositions for the treatment of infections |